Please ensure Javascript is enabled for purposes of website accessibility

Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come

By Brian Orelli, PhD - Updated May 6, 2019 at 10:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Additional drug approvals and launches are on the way.

Alnylam Pharmaceuticals (ALNY -2.93%) continued its launch of Onpattro in the first quarter, doubling the number of patients taking the drug from the end of the year to the end of the first quarter.

Alnylam Pharmaceuticals results: The raw numbers

Metric

Q1 2019

Q1 2018

Year-Over-Year Change

Revenue

$33.3 million

$21.9 million

52%

Income from operations (loss)

($188.8 million)

($147.4 million)

N/A

Earnings per share

($1.73)

($1.41)

N/A

Data source: Alnylam Pharmaceuticals.

What happened with Alnylam Pharmaceuticals this quarter?

  • Sales of Onpattro, which treats hereditary transthyretin-mediated amyloidosis (ATTR), came in at $26.3 million, more than double the $12.1 million in the fourth quarter.
  • In the first quarter, 90% of the start forms received came from newly identified patients who hadn't been treated in the expanded access program, suggesting the sales force is getting the word out about the new medication.
  • Collaboration revenue fell year over year due to a one-time milestone payment from Sanofi in the year-ago quarter.
  • In March, Alnylam reported positive phase 3 clinical trial data for givosiran, which treats a nervous system disease called acute hepatic porphyria.
  • With a pipeline of drug candidates to fund, Alnylam won't be profitable anytime soon, but the company has a substantial cash runway with $1.29 billion in the bank, after raising $382 million in a secondary offering in January.
  • Alnylam will also get another $800 million as part of a recently announced drug development deal with Regeneron Pharmaceuticals that is scheduled to close this quarter.
Doctor talking to a patient in front of a window

Image source: Getty Images.

What management had to say

Alnylam's president Barry Greene laid out some additional details on the prescribers, which could be helpful as the company tries to expand the approval of Onpatro into ATTR patients with heart complications: "Of note, 55% of start forms in Q1 came from cardiologists, which we believe reflects the mixed phenotype patient population and continued recognition of polyneuropathy as a major disease manifestation even in patients who may initially present with cardiac manifestations, and therefore be under the care of a cardiologist for their disease. We're also very encouraged by the number of new prescribing physicians and the number of physicians who have submitted multiple prescriptions."

On the patient side, Greene noted that Onpattro is competing well with Pfizer's (PFE -2.35%) tafamidis, which will likely be approved in the U.S. in the near future after posting solid phase 3 data last year. "In addition to naive patients, we are observing patients and physicians switching to Onpatrro from other products, including tafamidis, which is approved in the EU and reimbursed in many countries," Greene said.

Looking forward

Management didn't give revenue guidance, which is fair given the dynamic nature of a drug launch.

On the pipeline front, Alnylam expects to submit marketing applications for givosiran to regulators in the U.S. and EU in the middle of this year, setting up approvals later this year or early next year.

In the third quarter, investors should expect results from three phase 3 clinical trials testing inclisiran, the cholesterol lowering drug Alnylam is developing with The Medicines Company (MDCO). Also this year, Alnylam plans to present phase 3 data for lumasiran, which treats a kidney disease called primary hyperoxaluria type 1.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$142.20 (-2.93%) $-4.29
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.66 (-2.35%) $-1.22
The Medicines Company Stock Quote
The Medicines Company
MDCO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.